-+ 0.00%
-+ 0.00%
-+ 0.00%

BioCryst Pharma Announces New Real-World Evidence On Use Of Once-Daily ORLADEYO For Patients With Hereditary Angioedema, Showing Reductions In Hospitalizations And Emergency Department Visits

Benzinga·11/13/2026 12:06:08

—Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO® from another prophylactic therapy—

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of once-daily ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with hereditary angioedema (HAE) aged 2 and older, showing reductions in hospitalizations and emergency department visits following ORLADEYO initiation in patients new to long-term prophylactic therapy (LTP) and in patients switching to ORLADEYO from another LTP.

This practice-informing research will be featured across two poster presentations during the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting taking place in Phoenix, Arizona, November 12-16.